{
    "clinical_study": {
        "@rank": "51904", 
        "arm_group": [
            {
                "arm_group_label": "OnabotulinumtoxinA", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12."
            }, 
            {
                "arm_group_label": "Placebo (Normal saline)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I)\n      Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA\n      (BOTOX\u00ae) in adults with chronic migraine."
        }, 
        "brief_title": "Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX\u00ae)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of chronic migraine for at least 6 months prior to the screening visit\n\n          -  Fifteen or more headache days during the 4-week screening period (\u22654 headache\n             episodes lasting \u22654 hours and \u226550 % of headache days are migraine)\n\n        Exclusion Criteria:\n\n          -  Conditions causing chronic facial pain such as Temporomandibular Disorder (TMD) and\n             fibromyalgia\n\n          -  Use of headache prophylaxis medication within 4 weeks of the screening visit\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis\n\n          -  Previous use of any botulinum toxin of any serotype for any reason\n\n          -  Skin infections or acne that would interfere with the injection sites\n\n          -  Acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction,\n             dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block\n             treatments, or injection of anesthetics/steroids within 4 weeks of screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833130", 
            "org_study_id": "GMA-BTX-CM-12-545"
        }, 
        "intervention": [
            {
                "arm_group_label": "OnabotulinumtoxinA", 
                "description": "OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.", 
                "intervention_name": "OnabotulinumtoxinA", 
                "intervention_type": "Biological", 
                "other_name": [
                    "botulinum toxin Type A", 
                    "BOTOX\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Placebo (Normal saline)", 
                "description": "Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.", 
                "intervention_name": "Normal saline (placebo)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in the Assessment of Chronic Migraine Impacts (ACM-I) Total Score Using a 6-Point Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833130"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}